AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1328400 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% all-trans retinoic acid for 2 weeks
Number of subjects: 0
Study 1328400 — intervention group
Group type: EXPERIMENTAL
Intervention: Low concentration of retinoic acid (10(‐11) M)
Number of subjects: 0
Study 1328400 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration of retinoic acid (10(‐7) M)
Number of subjects: 0
Study 1328400 — intervention group
Group type: EXPERIMENTAL
Intervention: Up to 10(‐7) M retinoic acid
Number of subjects: 0
Study 6833677 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled verapamil
Number of subjects: 15
Study 6833677 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 15
Study 6833677 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled verapamil (before a single inhalation test)
Number of subjects: 15
Study 6833677 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 15
Study 31607726 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional septoplasty (CS)
Number of subjects: 50
Study 31607726 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic septoplasty (ES)
Number of subjects: 50
Study 29576857 — intervention group
Group type: EXPERIMENTAL
Intervention: Naringenin (20 mg daily)
Number of subjects: 95
Study 29576857 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 mg daily)
Number of subjects: 95
Study 27088545 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic antimicrobial therapy for all episodes of AB occurring ≤24 months after transplantation (53 patients)
Number of subjects: 112
Study 27088545 — intervention group
Group type: COMPARATOR
Intervention: No antimicrobial therapy (59 patients)
Number of subjects: 112
Study 27088545 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic antimicrobial therapy for AB (26 patients, per-protocol)
Number of subjects: 112
Study 27088545 — intervention group
Group type: COMPARATOR
Intervention: No antimicrobial therapy (50 patients, per-protocol)
Number of subjects: 112
Study 27088545 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic screening and treatment of AB
Number of subjects: 112
Study 24448046 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected sleep periods (midnight to 3:00 AM and 3:00 to 6:00 AM)
Number of subjects: 0
Study 24448046 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected sleep periods (late shift)
Number of subjects: 0
Study 24448046 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected sleep periods
Number of subjects: 0
Study 24448046 — intervention group
Group type: COMPARATOR
Intervention: Standard intern schedule
Number of subjects: 0
Study 21463799 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid supplement (24 g of an oral supplement containing a leucine metabolite, glutamine, and arginine twice daily)
Number of subjects: 30
Study 21463799 — intervention group
Group type: COMPARATOR
Intervention: Control group (no amino acid supplement)
Number of subjects: 30
Study 19539268 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 43
Study 19539268 — intervention group
Group type: COMPARATOR
Intervention: Sham depletion
Number of subjects: 43
Study 16936991 — intervention group
Group type: EXPERIMENTAL
Intervention: Group DE (hypocaloric diet + aerobic physical activity 1 hour/day 3 times a week)
Number of subjects: 50
Study 16936991 — intervention group
Group type: COMPARATOR
Intervention: Group D (hypocaloric diet only)
Number of subjects: 50
Study 15133538 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 0
Study 15133538 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 0
Study 11117774 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal clindamycin (one-week course)
Number of subjects: 101
Study 11117774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 9068344 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.6 mg
Number of subjects: 10
Study 9068344 — intervention group
Group type: COMPARATOR
Intervention: Control (no mivacurium)
Number of subjects: 10
Study 8453193 — intervention group
Group type: COMPARATOR
Intervention: Calcium 600 mg/day
Number of subjects: 36
Study 8453193 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus etidronate sodium 400 mg/day for 14 days every 3 months
Number of subjects: 36
Study 8453193 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus etidronate plus phosphate (1 g twice daily for 3 days before etidronate)
Number of subjects: 36
Study 3458431 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin Regimen A (40‐60 mg/m2 every three weeks)
Number of subjects: 41
Study 3458431 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin Regimen B (20‐30 mg/m2/day for 3 days every three weeks)
Number of subjects: 41
Study 1176325 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal selective vagotomy
Number of subjects: 50
Study 1176325 — intervention group
Group type: COMPARATOR
Intervention: Proximal selective vagotomy with pyloroplasty
Number of subjects: 50
Study 31091608 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose Hepatitis B vaccine (HepB) administered on a 0-6 month schedule
Number of subjects: 629
Study 31091608 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dose Hepatitis B vaccine (HepB) administered on a 0-1-6 month schedule
Number of subjects: 629
Study 31091608 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenge dose of Hepatitis B vaccine (HepB)
Number of subjects: 629
Study 31091608 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with anti-HBs titer <4, 4-6, and 7-9 mIU/ml at follow-up
Number of subjects: 629
Study 28577674 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI) for STEMI
Number of subjects: 2679
Study 28577674 — intervention group
Group type: COMPARATOR
Intervention: Control groups (no specific intervention mentioned)
Number of subjects: 2679
Study 25460337 — intervention group
Group type: EXPERIMENTAL
Intervention: Keys to Healthy Family Child Care Homes intervention
Number of subjects: 1500000
Study 23065023 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compound (200 μg selenium, 30 mg zinc, 2 mg vitamin A, 180 mg vitamin C, 30 mg vitamin E)
Number of subjects: 411
Study 23065023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study 23065023 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compound
Number of subjects: 411
Study 21684109 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser keratome
Number of subjects: 51
Study 21684109 — intervention group
Group type: COMPARATOR
Intervention: Mechanical keratome
Number of subjects: 51
Study 18723240 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT screening annually for 4 years
Number of subjects: 3206
Study 18723240 — intervention group
Group type: COMPARATOR
Intervention: No screening (control)
Number of subjects: 3206
Study 16456417 — intervention group
Group type: EXPERIMENTAL
Intervention: Pureed beef
Number of subjects: 88
Study 16456417 — intervention group
Group type: COMPARATOR
Intervention: Iron-fortified infant cereal
Number of subjects: 88
Study 15360790 — intervention group
Group type: EXPERIMENTAL
Intervention: Alerted clinicians (received the alert)
Number of subjects: 1076
Study 15360790 — intervention group
Group type: COMPARATOR
Intervention: Control clinicians (did not receive the alert)
Number of subjects: 1076
Study 11265827 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer Choices program
Number of subjects: 20
Study 9408114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) treatment (0.4 g/kg for five consecutive days)
Number of subjects: 5
Study 9408114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) maintenance treatment (0.4 g/kg weekly)
Number of subjects: 5
Study 9408114 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 5
Study 8496997 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feeding (target, < 24 hours)
Number of subjects: 52
Study 8496997 — intervention group
Group type: COMPARATOR
Intervention: Late enteral feeding (target, 72 hours)
Number of subjects: 52
Study 8496997 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feeding
Number of subjects: 52
Study 8496997 — intervention group
Group type: COMPARATOR
Intervention: Late enteral feeding
Number of subjects: 52
Study 2894489 — intervention group
Group type: EXPERIMENTAL
Intervention: oxprenolol
Number of subjects: 9
Study 2894489 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 9
Study 2894489 — intervention group
Group type: EXPERIMENTAL
Intervention: prenalterol
Number of subjects: 9
Study 2894489 — intervention group
Group type: EXPERIMENTAL
Intervention: phentolamine
Number of subjects: 9
Study 2894489 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine
Number of subjects: 9
Study 2894489 — intervention group
Group type: EXPERIMENTAL
Intervention: nitroglycerin
Number of subjects: 9
Study 2894489 — intervention group
Group type: EXPERIMENTAL
Intervention: angiotensin II
Number of subjects: 9
Study 2894489 — intervention group
Group type: EXPERIMENTAL
Intervention: frusemide
Number of subjects: 9
Study 2894489 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 31019117 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior subcutaneous transposition of the ulnar nerve
Number of subjects: 55
Study 31019117 — intervention group
Group type: COMPARATOR
Intervention: Simple decompression of the ulnar nerve
Number of subjects: 55
Study 31019117 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (comparison)
Number of subjects: 55
Study 27769562 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day bismuth quadruple therapy (bismuth tripotassium dicitrate 300 mg four times a day, lansoprazole 30 mg twice daily, tetracycline 500 mg four times a day, and metronidazole 500 mg three times a day)
Number of subjects: 1620
Study 27769562 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day concomitant therapy (lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg, all given twice daily)
Number of subjects: 1620
Study 27769562 — intervention group
Group type: COMPARATOR
Intervention: 14-day triple therapy (lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg, all given twice daily)
Number of subjects: 1620
Study 24626605 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise (20 sessions, 5 times per week for 4 weeks at 32-33 °C)
Number of subjects: 69
Study 24626605 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise (demonstrated by a physiotherapist and followed by an exercise manual)
Number of subjects: 69
Study 24626605 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Number of subjects: 69
Study 24139140 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex implementation strategy (guideline facilitator visits, stratification tools, quality reports)
Number of subjects: 2700
Study 24139140 — intervention group
Group type: COMPARATOR
Intervention: Simple implementation strategy
Number of subjects: 2700
Study 24139140 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex implementation strategy
Number of subjects: 2700
Study 20942614 — intervention group
Group type: EXPERIMENTAL
Intervention: Two tablets of ibuprofen 200 mg/paracetamol 500 mg
Number of subjects: 94
Study 20942614 — intervention group
Group type: EXPERIMENTAL
Intervention: One tablet of ibuprofen 200 mg/paracetamol 500 mg
Number of subjects: 94
Study 20942614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 19032172 — intervention group
Group type: EXPERIMENTAL
Intervention: Tincture of Opium (TOP) 6.66 mg morphine equivalents, twice daily
Number of subjects: 45
Study 19032172 — intervention group
Group type: EXPERIMENTAL
Intervention: Tincture of Opium (TOP) 13.3 mg morphine equivalents, twice daily
Number of subjects: 45
Study 19032172 — intervention group
Group type: EXPERIMENTAL
Intervention: Tincture of Opium (TOP) 20 mg morphine equivalents, twice daily
Number of subjects: 45
Study 19032172 — intervention group
Group type: EXPERIMENTAL
Intervention: Tincture of Opium (TOP) (all doses)
Number of subjects: 45
Study 16364595 — intervention group
Group type: EXPERIMENTAL
Intervention: Octyl-2-cyanoacrylate (Dermabond)
Number of subjects: 45
Study 16364595 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 45
Study 11062193 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin (800 mg perorally once daily for 10 days)
Number of subjects: 20
Study 11062193 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin (500 mg bid for 10 days)
Number of subjects: 20
Study 11062193 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin
Number of subjects: 20
Study 11062193 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 20
Study 11062193 — intervention group
Group type: EXPERIMENTAL
Intervention: Both telithromycin and clarithromycin
Number of subjects: 20
Study 9516902 — intervention group
Group type: EXPERIMENTAL
Intervention: BAYx 1005
Number of subjects: 16
Study 9516902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8436153 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 2
Study 8436153 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 25 mg
Number of subjects: 2
Study 8436153 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 75 mg and Captopril 25 mg (combined treatment)
Number of subjects: 2
Study 8436153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 3717319 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral therapy to the normal extremity
Number of subjects: 20
Study 3717319 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 20
Study 3717319 — intervention group
Group type: EXPERIMENTAL
Intervention: Range of motion exercises
Number of subjects: 20
Study 31364169 — intervention group
Group type: EXPERIMENTAL
Intervention: CCBT+MCBT (child-focused CBT with CBT for maternal anxiety disorder)
Number of subjects: 211
Study 31364169 — intervention group
Group type: EXPERIMENTAL
Intervention: CCBT+MCI (child-focused CBT with intervention targeting mother-child interaction)
Number of subjects: 211
Study 31364169 — intervention group
Group type: COMPARATOR
Intervention: CCBT+Con (child-focused CBT with nonspecific control interventions)
Number of subjects: 211
Study 31364169 — intervention group
Group type: EXPERIMENTAL
Intervention: CCBT+MCI
Number of subjects: 211
Study 30591062 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-reduced high-protein (CRHP) diet
Number of subjects: 16
Study 30591062 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes (CD) diet
Number of subjects: 16
Study 27558577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 50,000 IU/month
Number of subjects: 90
Study 27558577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 100,000 IU/month
Number of subjects: 90
Study 27558577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 27558577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 100,000 IU/month (after adjustment)
Number of subjects: 90
Study 24772594 — intervention group
Group type: EXPERIMENTAL
Intervention: G-suit
Number of subjects: 10
Study 24772594 — intervention group
Group type: COMPARATOR
Intervention: Control group (no G-suit)
Number of subjects: 10
Study 23321187 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor biofeedback training
Number of subjects: 45
Study 23321187 — intervention group
Group type: COMPARATOR
Intervention: 1 mg tolterodine, orally, twice daily
Number of subjects: 45
Study 20860068 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (50-75 mg/day depending on weight)
Number of subjects: 38
Study 20860068 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (20-30 mg/day depending on weight)
Number of subjects: 38
Study 18546233 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 24
Study 18546233 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 15957511 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed magnetic field therapy (PMFT)
Number of subjects: 25
Study 15957511 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 25
Study 12500022 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (200 mg once daily)
Number of subjects: 265
Study 12500022 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (20 mg once daily)
Number of subjects: 265
Study 12500022 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (200 mg once daily) in type IIa dyslipidemia
Number of subjects: 265
Study 12500022 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (20 mg once daily) in type IIa dyslipidemia
Number of subjects: 265
Study 12500022 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (200 mg once daily) in type IIb dyslipidemia
Number of subjects: 265
Study 12500022 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (20 mg once daily) in type IIb dyslipidemia
Number of subjects: 265
Study 10231206 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronidazole (OM) 500 mg for adults, 7‐10 mg/kg for children, administered 2‐3 hours before operation and continued postoperatively every 8 hours for three doses if mild to severely inflamed; for complicated appendicitis, the same dose for 3 to 6 days depending on pus presence.
Number of subjects: 1083
Study 10231206 — intervention group
Group type: COMPARATOR
Intervention: Ceftizoxime administered 2 to 3 hours before operation and postoperatively every 6 hours for three doses if mild to severely inflamed; complicated cases received penicillin, chloramphenicol, and gentamicin for 3 to 6 days depending on pus presence.
Number of subjects: 1083
Study 8744845 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of carteolol 2% and pilocarpine 2% (CBS 341 A) eye-drops
Number of subjects: 28
Study 8744845 — intervention group
Group type: COMPARATOR
Intervention: Carteolol 2% alone
Number of subjects: 28
Study 1986887 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow resistance breathing circuit
Number of subjects: 12
Study 1986887 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold-resistor breathing circuit
Number of subjects: 12
Study 1986887 — intervention group
Group type: COMPARATOR
Intervention: Control (other breathing circuits)
Number of subjects: 12
Study 6849168 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin plus clavulanic acid (A-CA)
Number of subjects: 44
Study 6849168 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 44
Study 31865938 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG ≥4.5 mmol/L
Number of subjects: 589
Study 31865938 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG ≥5.1 mmol/L
Number of subjects: 589
Study 31865938 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of one or more risk factors
Number of subjects: 589
Study 31865938 — intervention group
Group type: COMPARATOR
Intervention: Risk factor-based selective screening
Number of subjects: 589
Study 29899982 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging survey
Number of subjects: 1014
Study 29899982 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face interviews
Number of subjects: 1014
Study 25304282 — intervention group
Group type: EXPERIMENTAL
Intervention: Moorfields regression analysis (MRA)
Number of subjects: 230
Study 25304282 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma probability score (GPS)
Number of subjects: 230
Study 25304282 — intervention group
Group type: EXPERIMENTAL
Intervention: Discriminant functions
Number of subjects: 230
Study 24372613 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of l-theanine
Number of subjects: 14
Study 24372613 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of l-theanine
Number of subjects: 14
Study 24372613 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of l-theanine
Number of subjects: 14
Study 22158729 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet (0.5 g protein · kg BW(‐1) · d(‐1))
Number of subjects: 37
Study 22158729 — intervention group
Group type: COMPARATOR
Intervention: High protein diet (2.0 g protein · kg BW(‐1) · d(‐1))
Number of subjects: 37
Study 20518951 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate (GS)
Number of subjects: 0
Study 20518951 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 0
Study 20518951 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study 18339272 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metoprolol treatment
Number of subjects: 103
Study 18339272 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration salt treatment
Number of subjects: 103
Study 16355944 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine, 0.5 mg/kg
Number of subjects: 59
Study 16355944 — intervention group
Group type: COMPARATOR
Intervention: saline, 2 mL
Number of subjects: 59
Study 16355944 — intervention group
Group type: COMPARATOR
Intervention: ketamine, 1.2 mg/kg
Number of subjects: 59
Study 12617466 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed oil-based diet rich in mono- and polyunsaturated FA
Number of subjects: 75
Study 12617466 — intervention group
Group type: COMPARATOR
Intervention: Control diet rich in saturated FA
Number of subjects: 75
Study 12617466 — intervention group
Group type: EXPERIMENTAL
Intervention: FA 18:0 and 20:3
Number of subjects: 75
Study 12617466 — intervention group
Group type: EXPERIMENTAL
Intervention: FA 20:5 and 22:6
Number of subjects: 75
Study 9706940 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine-prilocaine cream (EMLA)
Number of subjects: 538
Study 7876652 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated HAV vaccine, 0.5 mL, with second and third doses at 1 and 2 months (Group A)
Number of subjects: 57
Study 7876652 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated HAV vaccine, 0.5 mL, with second and third doses at 1 and 6 months (Group B)
Number of subjects: 57
Study 7876652 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 57